CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CML is introducing U-TURBT, a disposable device aimed at improving bladder cancer treatment. By preventing tumor cell spillage during surgery, it reduces recurrence rates and enhances patient outcomes while lowering healthcare costs associated with additional treatments.
Bladder cancer represents the 9th most common malignancy worldwide and the 4th most common in men.
Globally approximately 2.5M people suffer from it, with 420,000 newly diagnosed cases each year.
In Europe, a total of 118,000 new cases and 52,000 deaths are estimated annually.
With population growth and ageing, the absolute incidence of bladder cancer might be further escalating.Despite the increasing incidences, the current treatments remain ineffective.
The gold standard Trans-Urethral Resecti…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
